Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma

Status: Closed to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03528408
• See news release

Abstracts/Posters/Presentations:

• Suthee Rapisuwon, Richard D. Carvajal, George Ansstas, Katy K. Tsai, Leonel Fernando Hernandez-Aya, Shaheer Khan, Sunandana Chandra, J. William Harbour, Jeffrey A. Sosman, Adil Daud, Christina Decatur, Deniz Ozisik, Ming Tony Tan, Michael B. Atkins, Sapna Pradyuman Patel. Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309). Presented as a rapid oral abstract at the 2024 ASCO Annual Meeting. See abstract. 
• S Rapisuwon, SP Patel, RD Carvajal, LF Hernandez-Aya, K Tsai, S Chandra, MT Tan, A Daud, JA Sosman, MB Atkins. Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma. Accepted to the 16th International Congress of the Society for Melanoma Research, Nov. 20-23, 2019, Salt Lake City, Utah. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.